Clinical trials: Dementia Alzheimers
Alzheimer Disease
Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy
Cognitive and memory disorders are characterized of Alzheimer disease. In addition, psychologic and behavioural symptoms, called speak neuropsychiatric symptoms, are frequents and play an important role in prognostic and…
- Trial name
- NCT01384344
- Testing
- observational
- Where
- France
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Dementia, Cognitive Impairment
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and…
- Conditions
- Dementia, Cognitive Impairment, Cognitive Decline, Alzheimer Disease
- Trial name
- NCT05607732
- Testing
- MyCog
- Where
- United States
- Volunteers
- 57,589 people
- Sponsor
- Northwestern University
Alzheimer's Disease, Agitation
Citalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
- Trial name
- CitAD (NCT00898807)
- Testing
- citalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- JHSPH Center for Clinical Trials
Amyloid, Medullary Thyroid Cancer
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Using excess tumour samples that contain amyoid, from patients with Medullary Thyroid Cancer, we aim to determine the structures of ex vivo amyloid fibrils from human tumour tissue samples and compare them with that of existing…
- Conditions
- Amyloid, Medullary Thyroid Cancer, Alzheimer Disease, Dementia
- Trial name
- NCT04760171
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Alzheimer's Disease
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
- Trial name
- STEADFAST (NCT02080364)
- Testing
- Azeliragon
- Where
- 115 sites in United States, Australia and 5 more
- Volunteers
- 880 people
- Sponsor
- vTv Therapeutics
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Alzheimer Disease, Oxidative Stress
Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's Disease
High lipid peroxidation and altered antioxidant defenses have been frequently reported in Alzheimer's disease patients. The purpose of this study is to investigate susceptibility to photo-oxidation of isolated erythrocyte…
- Conditions
- Alzheimer Disease, Oxidative Stress, Adrenocortical Hyperfunction
- Trial name
- NCT01707719
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Raffaele Antonelli Incalzi
Alzheimer Disease
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Trial name
- NCT06439992
- Testing
- 18F-Fluselenamyl
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lewy Body Disease, Alzheimer Disease
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals.
- Conditions
- Lewy Body Disease, Alzheimer Disease, Healthy
- Trial name
- NCT06057909
- Testing
- Magnetic Resonance Imaging, Electroencephalography, Electromyography
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer Disease (AD)
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside.
- Trial name
- N-AD (NCT07741071)
- Testing
- Nicotinamide Riboside (NR), Palacebo
- Where
- 2 sites in Norway
- Volunteers
- 270 people
- Sponsor
- Haukeland University Hospital
Alzheimer Disease, Cognitive Decline
40 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations
This study aims to compare the efficacy of different 40 Hz tACS protocols in entraining gamma oscillations, which are linked to various cognitive functions and play a significant role in cognitive impairments like Alzheimer's…
- Trial name
- NCT06740864
- Testing
- Transcranial alternating current stimulation
- Where
- Iran
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The National Brain Mapping Laboratory (NBML)
Alzheimer's Disease
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.
- Trial name
- NCT01825330
- Testing
- TMS and cognitive stimulation
- Where
- 10 sites in United States, Israel
- Volunteers
- 131 people
- Sponsor
- Neuronix Ltd
Mild Cognitive Impairment, Alzheimer Disease
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
The aim of this study is to find out whether a new image analysis technique called Cortical Disarray Measurement (CDM) could be used to help better diagnose Alzheimer's disease.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- CONGA (NCT05579236)
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA)
UPenn Observational Research Repository on Neurodegenerative Disease
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
- Conditions
- Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS)
- Trial name
- UNICORN (NCT04715399)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Optical Coherence Tomography, Optical Coherence Tomography Angiography
Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers
Alzheimer disease is hard, long and expensive to diagnose. In order to help the clinician, a new biomarker in Alzheimer disease seems to be very useful.
- Conditions
- Optical Coherence Tomography, Optical Coherence Tomography Angiography, Retinal Thickening, Alzheimer Disease
- Trial name
- RETEVAL (NCT04794634)
- Testing
- Optical coherence tomography (OCT), Optical coherence tomograpohy angiography (OCTA)
- Where
- France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Empaglifozin, Physiological Effects of Drugs
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Background: The drug empagliflozin treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood.
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT03852901
- Testing
- empagliflozin (Jardiance) 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease，Mild Cognitive Impairment
Cohort Study on Cognitive Decline in Elderly
Alzheimer's Disease (AD) prevention and control currently face severe challenges, with limited treatment options and effectiveness available. Once the disease progresses to the AD stage, it is essentially irreversible.
- Trial name
- NCT07093892
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Transcranial Random Noise, Electroencephalography
Effect of Transcranial Random Noise (tRNS) for Early Alzheimer's Disease
To investigate the treatment effect of Transcranial random noise (tRNS) on Alzheimer patients, and the underlying neural mechanism by EEG.
- Conditions
- Transcranial Random Noise, Electroencephalography, Alzheimer Disease
- Trial name
- NCT05891444
- Testing
- High frequency transcranial random noise
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Medical University
Healthy
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain.
- Trial name
- NCT01265394
- Testing
- [18F] Flutemetamol
- Where
- United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Subjective Cognitive Decline (SCD)
Personalized Brain Health Service and Dementia Prevention
This study evaluates the feasibility of implementing a Brain Health Service (BHS) to assess and reduce dementia risk in individuals with Subjective Cognitive Decline (SCD).
- Trial name
- B-HEALTH (NCT07698431)
- Testing
- Multimodal Lifestyle Intervention, Lifestyle Recommendations and Counseling
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.